Please login to the form below

Not currently logged in
Email:
Password:

Roche's early development head Richard Scheller to retire

Will be replaced by Michael Varney from the company's Genentech business
Roche's Richard Scheller

Richard Scheller is to step down as head of Roche's Genentech Research and Early Development (gRED) unit and retire at the end of the year.  

He will be replaced by Michael Varney, who is currently head of small molecule drug discovery at Genentech and whose appointment will also see his join Roche's enlarged corporate executive committee.  

Scheller (pictured right) joined Genentech in 2001 as senior vice president of research and was named executive vice president of research in September 2003 and appointed chief scientific officer in 2008.  

Severin Schwan, CEO of Roche, said: “I thank Richard Scheller for his outstanding contributions to the Roche Group. Genentech developed a number of important medicines under his leadership. Richard also contributed significantly to the successful integration of Genentech into the Roche Group.  

Roche's Michael Varney“It is my pleasure that with Mike Varney we could name a successor from within the gRED organisation. Mike brings a proven track record in the discovery and development of new medicines as well as considerable experience in leading research organisations.”  

Varney (pictured left) has been with Genentech since 2005, starting as vice president of small molecule drug discovery, and will begin his new role on 1 January 2015.

12th December 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics